A Phase 1 Dose-Escalation Study of LY2382770, a TGF-beta Monoclonal Antibody, in Patients with Metastatic Cancer
Latest Information Update: 04 May 2010
At a glance
- Drugs LY 2382770 (Primary)
- Indications Cancer
- Focus Adverse reactions
Most Recent Events
- 04 May 2010 New trial record.